Skip to main content

Table 3 Baseline parameters showing annual costs and utility values associated with BPH treatment

From: A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

Annual cost associated with treatment  
  Dutasteride US$ Fixed dose therapy US$  
Moderate BPH   338.82 Cost generated from cost data in two regional tertiary health centres in Nigeria
Severe BPH 223.53 338.82
TURP 484.97 484.97
AUR 29.41 29.41